These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23606169)

  • 1. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
    Buxhofer-Ausch V; Ausch C; Zeillinger R; Oberkanins C; Dandachi N; Reiner-Concin A; Kriegshäuser G
    Dis Markers; 2013; 34(3):171-7. PubMed ID: 23324583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
    Kwon MJ; Lee SE; Kang SY; Choi YL
    Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
    Bennani B; Gilles S; Fina F; Nanni I; Ibrahimi SA; Riffi AA; Nejjari C; Benajeh DA; El Abkari M; Martin PM; Ouafik L
    Int J Biol Markers; 2010; 25(4):179-84. PubMed ID: 21161938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
    Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
    Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients.
    Seekhuntod S; Thavarungkul P; Chaichanawongsaroj N
    PLoS One; 2016; 11(1):e0147672. PubMed ID: 26812617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
    Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
    BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
    Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
    BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
    Harlé A; Busser B; Rouyer M; Harter V; Genin P; Leroux A; Merlin JL
    Virchows Arch; 2013 Mar; 462(3):329-35. PubMed ID: 23400679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
    Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
    Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.